Single injection of ProLynx long-acting semaglutide produced 20% weight loss in diet-induced obese mice, which is comparable to multiple semaglutide injections over the same period SAN FRANCISCO, Dec. 2, 2024 /PRNewswire/ — ProLynx Inc., a biotechnology company developing proprietary…
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.